Mitsumasa Kishimoto

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 359 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +14

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

Désirée van der Heijde, In-Ho Song, Aileen L. Pangan et al. · The Lancet · 2019 · 346 citations · Full text

Medicine, Pharmacotherapy, Rheumatology +2

Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis

Iain B. McInnes, J. Anderson, Marina Magrey et al. · New England Journal of Medicine · 2021 · 301 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study

Anna Moltó, Adrien Etcheto, Désirée van der Heijde et al. · Annals of the Rheumatic Diseases · 2015 · 264 citations

Medicine, Internal Medicine, Epidemiology +12

2018 update of the APLAR recommendations for treatment of rheumatoid arthritis

Chak Sing Lau, Faith Li‐Ann Chia, Leonila F. Dans et al. · International Journal of Rheumatic Diseases · 2019 · 176 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +14